Company intelligence / Profile preview
H-CYTE
Tampa, Florida, United Stateshcyte.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
H-CYTE’s SkinDisc™ product has demonstrated significant early clinical results in wound healing and limb salvage with over 500 patients treated to date. Healing times are reported at four to nine weeks per application versus the standard of care’s twelve to twenty weeks. The company plans an FDA De Novo submission for SkinDisc™. BreatheEasy targets COPD via autologous IV infusion but appears pre-commercial.[1]
- Therapeutic areas
- PulmonologyDermatology
- Modalities
- Cellular therapeutics (including autologous cellular therapy)Active cellular matrix for wound healingAutologous IV infusion therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on H-CYTE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H-CYTE.